Fig. 7

TME subtype could predict response to ICIs. a The levels of immune score in different biopsy times (Chen et al.). b The stromal scores in different biopsy times (Chen et al.). c ICI responses of different TME subtypes (Chen et al.). d Sankey diagram revealed the subtype changes of patients at different time points (Chen et al.). e The immune scores in different biopsy times (GSE91061). f The stromal scores in different biopsy times (GSE91061). g ICI responses of different TME subtypes (GSE91061). h Sankey diagram revealed the subtype changes of patients at different time points (GSE91061). i ICI responses of different TME subtypes (GSE93157). j ICI responses of different TME subtypes (GSE67501). k ICI responses of different TME subtypes (GSE35640). l TME subtype was linked to PFS of patients with ICI treatment in GSE93157. ICI, immune checkpoint inhibitor; LUAD, lung adenocarcinoma; SKCM, skin cutaneous melanoma; HNSC, head and neck squamous cell carcinoma; TME, tumor microenvironment; HH, immune^high stromal^high; HL, immune^high stromal^low; LH, immune^low stromal^high; LL, immune^low stromal^low